Novel Therapies for Improved Patient
Outcomes in Metastatic Melanoma
A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.


This activity is valid from January 15, 2017 to January 31, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck & Co.

Description:
Melanoma is the most serious type of skin cancer and while it is the least common amongst skin cancers, it is by far the most deadly. In the early stages of melanoma, prognosis is usually good for patients but when the melanoma becomes unresectable/advanced and spreads to other areas of the body, prognosis is especially poor. The most common sites of such spread are under the skin (subcutaneous tissue) and other soft tissues (including lymph nodes), the lungs, liver, brain, and bone. Fortunately new therapy options have recently been approved for patients with melanoma. For many years, interleukin-2 (IL-2) was the primary therapy available for patients with advanced melanoma but new immunotherapies have become available. These therapies help the immune system sustain an active response in its attack on melanoma cells. Recently oncolytic viral therapy has also become available for melanoma patients with unresectable disease that has recurred after initial surgery. This session will review these emerging treatment options, their associated risks, and how individualized therapy and patient education can improve patient outcomes.

Upon Completion of this activity, participants will be able to:

  • Examine clinical data surrounding the safety, efficacy and recommended usage of immunotherapies and targeted therapies in the treatment of metastatic melanoma

  • Identify patients with metastatic melanoma who are candidates for immunotherapeutic regimens, or combination therapies, based on tumor characteristics and patient factors

  • Analyze the role of Anti–PD-1 immunotherapy, both alone and in combination, for patients with metastatic melanoma

  • Evaluate recently updated NCCN and ASCO management guidelines on the treatment of metastatic melanoma

  • Recognize the importance of metastatic melanoma patients actively participating in their treatment decisions and health management
     

Faculty: Matthew H. Taylor, MD
Director, Phase I Clinical Trials Clinic
Assistant Professor of Medicine
Division of Hematology & Medical Oncology
Oregon Health & Science University

Disclosure:

Dr. Taylor serves on an advisory panel for BluePrint Medicines, Bristol-Myers Squibb Eisai, Inc and Trillium Pharma.. His presentation has been peer reviewed.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This activity is supported by an educational grant from
Merck & Co.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue